LMY-252

N/A

Report date: 2025/09/01 13:59:45

Base Information

Drug NameLMY-252

Drug Alias NameLMY-252

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Gamma delta T-cell therapy

Mechanisms of ActionT lymphocyte replacements

TargetsUpdating

Therapy Area/IndicationsLung NeoplasmsColorectal Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesLuminary Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesLuminary Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsLung NeoplasmsColorectal Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A